Q3 2023 Cibus Inc Earnings Call
[music].
Good afternoon, and welcome to the <unk> third quarter 2023 results conference call all participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask questions.
That time, if you have a question. Please press the one followed by the four on your telephone keypad. If at any time during the conference you need to reach an operator. Please press Star Zero. Please also note today's event is being recorded at this time I'd like to turn the conference over to Wade King Chief Financial Officer, Sir. Please go ahead.
Thank you and good afternoon.
It's just we'd king the chief financial officer of cheapest.
I'd like to thank you for taking time to join US for <unk> third quarter 2023 financial results and corporate update conference call and webcast.
With me today is worthy rigs, our co founder and Chief Executive Officer and Chairman.
And Peter Beaven, co founder President and Chief operating Officer.
Before we begin the conference call I'd like to remind everyone that statements made on the call and webcast.
Just regarding future financial results and future operational goals and industry prospects are forward looking and maybe subject to a number of risks and uncertainties that could cause actual results could differ materially from those described in the call.
Please refer to see this FCC filings for a list of associated risks.
This conference call is being webcast.
Test link along with our press release and corporate presentation are available on the Investor Relations section of <unk> Dot com too.
Assist in your analysis of the business with that I would now like to turn the call over to Mr. Rigs go ahead Laurie.
Thanks, Wade and welcome to everybody on the call I'll begin by highlighting several of our recent business or commercial updates then Peter and I will walk you through where we are and where we are headed lastly.
Lastly, Wade will finish with a brief discussion of the financials. The goal of this format is to provide you with an educational overview of our business. It's pipeline their prospects. So you better equipped with a solid foundation.
Understand our company.
To track our events and progress.
With that I'd like to discuss some of our recent business a commercial update.
Since going public in June of this year, we have been laser focused on driving our evolution from an R&D company to a commercial company.
As part of this transition we underwent a strategic alignment is October aimed at bringing enhanced focus to our primary commercial goal, which is furthering the advancement of our commercial activities.
All of our resources and operations are all centered on completing the launch of our initial trades importantly, our three developed trades pod Chad reduction often referred to as <unk> come to work and then rise H T. One herbicide tolerance number one H G III, who as I tell her separate three as well as <unk>.
Advancement of our soybean platform.
Bolstering its development award grants trades seekers or assistance and HQ, two and both canola and soybean.
Notably.
Our realigned efforts have captured this focus and priorities.
Speak to our progress in each of these traits a little later on.
Concurrent with our strategic realignment. We are also implementing some necessary cost reduction measures with the objective of preserving capital resources for the advancement of these five trades.
We believe that refocusing.
Strength in top priorities will position us well to achieve our strategic objectives in a more timely manner.
Working hard to make sure that happens.
So let me take you through our five trades wheat crop business model.
The royalties haven't started yet.
Utilization efforts are well underway there.
They are centered around advancing five trades with applications in three major crops rice.
Sure Saul.
Yes.
Combined we believe this represents the addressable market opportunity of over 250 million acres and over $1 billion in potential royalties across Coca Cola.
In soybeans.
We believe that this five trades III crop model is just the beginning of what our capabilities can ultimately address.
One of our key accomplishments of our scientists has been their mastery of oligonucleotides directed mutagenesis, our single cell technology, and our production system supporting each crop platform.
For many even bigger accomplishment is the fact that with this technology platform the team and see this as being able to generate a product pipeline of five important trades. Three of these traits are fully developed have multiple years of successful field trials and strong intellectual property important to free trade, we now have a <unk>.
Strong customer base.
In addition, <unk> built two crop platforms that could lower waste as well as being close to a third crop platform as soybean.
Our soybean platform is under active development for several years and we expect to have the soybean platform operational Q4 2023.
Now that we have these three creates developed commercializing them through a high throughput and process.
Accelerating our development timeline, we are very excited about the prospects for these 30 trades in this process. We ended our customers' proprietary germplasm and then transfer the germ plasm back to them with our trade.
Cannot execute this process very quickly, allowing the customer to accelerate the commercialization process.
<unk> satisfied and the results are confirmed then.
The customer develops or registration dose yet initiated its marketing plan bulks are going to see the inventory distributes the seed to flowers at which point the royalties begin being paid to see this.
We consider our first trade product to VR pods shatter resistant trade <unk> its strengths and the seats alone could overseas, which protects the crops and extreme weather conditions, we have shown <unk> efficacy in multiple field trials.
Based on these field trials, we now have 10 different customers. So we estimate represent over 20 million acres of La <unk>.
These crops and have started returning to customers the elite germplasm with Rps are treated.
As we have stated that we expect to complete transfers to six customers in 2023. Additionally, we expect <unk> for the transfer of the remaining customers and increase our market penetration with additional customers where.
We estimate that the annual royalties from <unk> could be approximately $200 million.
Yeah.
In addition to <unk> with to develop trades, our HD one HD three in the race there.
They're important gene edited traits for herbicide tolerance or weed management.
Over 95% of canola soybean and corn currently utilized GMO based herbicides trades through each management.
<unk> has never had GMO trades. This is why these two trades that are in high demand and rice, we have already transferred our first HD one HD three traits in rice to neutral for the North American market.
Now have three customers, who we believe represent over 4 million acres in north and South America.
We expect additional customers in North America, and South America in 2024, we estimate that the annual trade Worldview three is for <unk>, three and raise could be approximately $150 million a year.
These traits are now fully developed and validated and similar to our work in <unk>, we'll be tracking to progression to customers commercial lines that will generate our future royalty streams.
The progression of these three trades has accelerated significantly in 2023, we're shifting as it trades back to customers are also adding new customers across both canola and soybean we look forward to updating you on the progress of these three trades in these two crops over the preceding quarters.
In addition to our developed trades are two advanced trades are critically important.
They are both multi crop traits, meaning they have potential efficacy across multiple crop types.
The first events tree is H T two or herbicide resistant number two for weed management.
Because of the extensive overuse of certain modes of action over the last 20 years, many weeds have become resistant to those herbicides for crops like canola soybean.
Dense of demand for new broad spectrum, herbicides and associated herbicides trades target broadleaf weeds that as the market for HD too.
We expect important greenhouse results next summer for this trip.
Because of this demand both canola and soybean we believe there's a potential to be the first year.
Trade to exceed $100 million acres.
The industry estimates of GMO based herbicide trades are utilized currently although over 300 million planted acres.
The second advanced trade it for square, a kidney or a white mold resistance.
<unk> is the most damaging disease in canola and one of the major diseases impacting soybean.
As it is used right. This was a single motive action trades in order to be durable this trade needs to address multiple parts of the disease condition. If successful this would be the first major disease trip applicable for multiple crops.
This trade is successful and deployed across both canola and soybean. We believe that this trade has the potential to be the largest trade to date.
The development of these two trades have progressed well in 2023 over the next year as we will track the progression of these two trades also and their advancement to customers commercial lives into the royalty payments.
These traits and their royalty payments will be a significant component of our economic base and profitability will follow this progress on a quarterly basis very closely.
Soybean is the last component of our five grade III crop business plan.
We've had significant progress in completing our soybean singles so as a platform.
As we have stated we still believe that we will complete the development of its platform of FY 2023.
Over the next few years, we will track the progression of our soybean business. Once we have achieved our platform. We expect significant growth in soybean customers based on initial discussions we have had to date.
As a large 200 million plus acre crop just north and South America. Many of the major soybean seed companies are already customers, you'll see those other crops. We believe its soybeans will be a major contributor of our economics basically forward.
Central pillar of the growth of gene editing in agriculture.
As is clear.
Our five trade three crop model as the central focus of our corporate strategy.
We intend to track the progression of each trade is deployed into elite germplasm and the progressive each will be central to our quarterly updates going forward as each trade by crop combinations starts generating royalty revenue.
With that I'd like to pass the call over to Peter for his remarks.
Thank you Barry and good afternoon to everybody.
Is it really just mentioned C. This is five three crops model is at the forefront of agriculture analog to digital environment, we say that because with gene editing traits. We are fundamentally changing the scale and speed of trait development in crops.
The technology behind our rapid type development system Tds allows us to edit a single cell extracted from clients that represent the best plant genetics in the industry.
10 days.
As a lead Gen platform.
The edited cells from that even Gen. Pausing then re generated into.
Identical elite germplasm with the targeted edits.
This really is the key point of differentiation at savings from other gene editing technologies.
We have significantly reduced the time and expense of bringing new innovations to seed companies.
Our focus continues to be scaling and acceleration of customers gene edited elite genetics.
He is how high throughput gene entity.
Outright machine works.
Once we secure approval and you see company to edit.
Gen program.
And we physically received the gen plasma farmland the developing of our product beginning as it enters the Triton machine.
As we shared last quarter, we opened the first high throughput.
<unk> automated gene editing facility.
As Marty mentioned, we are excited to see our first customers and is a gen pleasant cancels in 2023.
And this new facility.
I live in additional product at scale and acceleration over the next 24 months.
It's important to note that when we add the new try to Apple falling on we don't have to invest in an entirely new machine.
Instead, we simply use a new set of editing reagents.
When we add a new crop to the platform, we just add in plug and play automation solutions, while applying a plant.
Tissue culture experience can facilitate any changes.
It'd be required.
The relative simplicity of Amazon and the efficiency that it allows is the basis for our rapid development.
While also helping cotai all significant capex investment as we scale and accelerate our business.
When do we save our customers elite germplasm.
It is price has been running through our technician.
Once the molecular conformation of the edit is complete we validate the quality of that.
The efficiency of the trials and ensure the elite line is identical to what we initially received with the solid exception, albeit at three Meg.
This quality assurance is absolutely critical for our customers.
We then interest paid to generate a small supply of sage to hand back to the customer so they can begin.
<unk> process.
We envision this price stays lasting between 18 to 24 months.
It is important to note that.
And I'd say this out really with on how developed site has been completed and voice rooms, greenhouses and field trialing.
For many years to showcase the process prior to entering the high throughput editing process with customers to net.
This early work we have completed provides excellent guidance for our customers on how we can accelerate that.
The commercial pricing.
Cutting down what has historically been a decade long price days to a few years.
Truly revolutionary and underpins our strategy to build a scaled high margin high free cash flowing business.
Back to you Roy.
<unk>.
Thanks, Peter and summary, our commercialization efforts are well underway and are centered around advancing five trades with applications in the three major crops rice canola.
<unk>.
Combined we believe this represents an addressable market opportunity of over $1 billion in royalties and our three crop five trade model is just the beginning of what our capabilities can also fully address.
In addition to the five trades re crop commercialization process there are other elements.
Also important to our commercialization efforts.
Somewhere in agriculture is a key time for field studies and this year, we had an extensive field trials scheduled for each of our trades.
We also work with our customers in the field as we work together to launch our three to fill up trades.
Additionally, in the third quarter, we established our first multi locational deal that works for spirits in year wait Volcker assistant testing of various modes of action.
That are progressing through our pipeline.
This field performance network is critical to advance and demonstrate the efficacy of existing and additional modes of action per square 10 year resistance.
Korea has also been a key year in the development of a new global regulatory regime for gene editing technology.
With gene editing technology that does not use transfusions.
In recent years, we have seen introduction of policy.
Use of gene editing without the use of <unk> in multiple countries around the world.
Most recently on July 5th EU College of Commissioners adopted the European Commission proposal and the regulation of plants obtained the genomic techniques often referred to as in GTS.
Post regulation identifies conventional light category and GT products that would be regulating this convention varieties.
Bring you closer to that of trading partners in North and South America, Australia and Japan.
And the proposal the commission highlights the potential of N. GT is to contribute to a more sustainable agriculture climate resilience and food security.
Under this proposal products and see this as gene editing platform would be considered conventional like.
The EU is important for many reasons first it is a critical bellwether for the rest of the world.
It represents over 100 million acres.
The GMO trade technologies and third.
Third there are approximately 20 million acres of winter oilseed rape grown in Europe, which tries to directly into our own strategy.
<unk> trade has been developed for this market and we began field trials just trade in the U K in 2023.
The market is also suitable for other against trade within our colonial pipeline.
These are major steps in the progression of our products and technology on a global basis, we will continue to monitor and update the progress on the regulatory advances as they occur.
Curve, but we're on target for gene editing technology to be globally approved methodology for advancing plant trades now I'll pass the call onto <unk>, who will review our financials.
Thank you Laurie.
Looking at our financials for the third quarter.
Cash and cash equivalents was 31 9 million as of September 32023.
We believe our cash and cash equivalents were unable us to fund planned operating expenses and capital expenditure requirements into the first quarter of 2024.
R&D expense was $17 5 million towards the third quarter of 2023.
Two 3 million in the year ago period.
The increase was primarily related to increased lab supply and facility expenses and.
An increase in employee head count and an increase in stock based compensation expense for restricted stock Awards.
SG&A expense was $8 8 million for the third quarter of 2023.
Compared to $3 2 million in the year ago period.
The increase was primarily related to an increase in head count.
Increased consulting and legal fees.
The increase in stock based compensation expense for restricted stock grants.
Non operating expense.
<unk> 9 million for the third quarter 2023.
Compared to a nonoperating income of <unk> 3 million and a year ago period.
The decrease was due to changes in the fair value liability classified class a common stock warrants.
Net loss was $34 5 million third quarter of 2023.
To a net loss of 6 million in the year ago period.
For additional details about our financials for third quarter of 2023, please refer to our press release and <unk>.
Are you speaking, yes, you should.
That concludes our financial discussion worry back to you for your closing remarks.
Thanks Wade.
Thanks to everyone for listening in.
I can't tell you how excited we are to see what the future brings receivers.
We believe that we are at historic inflection point, where we can for the first time bring rapid innovation industry is hungry to solve the world's food shortages.
Tailwind from an improved regulatory environment and breakthroughs in trade development, our experienced team at CBS is executing on the opportunities ahead of us as we continue to advance the deployment of our traits to our customers' elite germplasm to enhance their product offerings for the benefit of their farmer customer.
We look forward to updating you on the next call.
Operator that concludes our prepared remarks, we'll open up the call for Q&A.
Thank you if you would like to register a question. Please press the one followed by the four on your telephone you will hear a three tone prompt you acknowledge your request and if your question has been answered and you would like to withdraw your registration. Please press the one followed by the Street.
And our first question is from the line of Bobby Burleson from Canaccord. Please go ahead.
Thank you.
Yeah, Hi, Gerry and team.
So.
Yeah I guess my first question is just around <unk>.
Helping us understand how to prioritize some of the.
Efforts currently underway. So if we can just look at.
Some of the commercialization process progress that you guys announced.
That took place over the quarter.
Maybe help us rank that in terms of significant bye.
Total addressable market opportunity or.
Timeline or both.
Thanks, Bob.
I think that's a great question.
We have these five trades.
Totally realize they're prioritizing in our prioritized is really these three developed trades and so the emphasis here is what happened in the last quarter to get rice further along but what happened in the last quarter to get pod chatter further along.
I'll, let Peter talk to some of it but.
Because of the work we've done in rice.
We now have really big debate, but Latin America, and we've already signed one big customer, which we think represents plus or minus 3 million acres that we have a number of others rather than the target and so a real progress has been the development. We've done in the commercial customers. So these are customers who are now in the process of sending us their germplasm.
Putting our trade spend their germplasm and so.
Goal is over the next year to be able to take these germplasm to get it back to them with their trade so they could launch it.
Yes, hopefully you'll follow as the contracts, we're signing of acreage that go with it and how fast we can turnaround the germ plasm.
Golden this businesses too.
These germ plasm 10 People's crops. So they can bulk up alone.
We're part of the launching process. So when we ship back we'll have a pretty good sense of the timing of when they bulk up into when they go in and touch.
Todd shatter.
What's really interesting about <unk> first that we.
We have 10 trades, we've added them or we're at a different process of launching back but like Peter to talk about the big thing in part shatter is.
The building, we were now able to do with field studies and field studies with the customers and the combination of getting them their germplasm in their field studies.
This model will get all three of these trades are going to be ready to your planning around the same time, but for each one of these things we need to be really clear about the things we're doing to get them ready for that time.
Two.
Be able to say whether things got delayed but more importantly to tell you why we're encouraged by where they are and how to think about revenues Peter you want to throw a little bit on plants.
<unk>.
I do.
Thanks, Robbie for the question and thanks Rory.
I think the best way to think about our progress.
And I'm Gonna, specifically talked about granola Pud Shadow is that as Barry mentioned, we have 10 customers.
<unk>, whose genetics and I've mentioned it on the call elite germplasm.
In our hands and we're in the midst of transferring back to that so.
So far in 2023 were transferred to other customer lines back.
The whole group.
ALLETE genetics that we have in our hand equates to accessing it as much as 20 million acres over time, but what's exciting for us is that that transfers the starting to occur and then their field trials that we're doing.
Uh huh.
With the canola hybrids with potsherd attrite in them.
Uh huh.
We were very successful this last summer.
So excited to see that in the field and customer genetics.
And then.
This winter, we will be looking at canola hybrids.
In winter nurseries, and we've really moved to that next level of pre commercialization performance evaluation in 2024.
Thanks, Peter and then probably the other thing we were so focused on these three crops in St. Pete tracing to crops, we will.
Kansas ignore the fact that we're so excited about soybeans, we're doing in the GDN germ plasm, but we really are excited that we will be able to finish that this year.
And once we do that it's really the big opportunity that suddenly we believe one of the people think we have this single cell model that regenerate is back into a plant in soybean that we have a lot of customers from display being built there is just a really big opportunity to build this business.
That's right.
Alright helpful.
Yes.
Great and then just a follow up.
This EU draft.
On their proposed regulatory treatment.
I was calling and Bt's cut I guess.
Lots of acronyms.
It sounds very positive.
And I'm wondering can you kind of.
Draw a parallel between what they're talking about doing it and what Canada is already done.
And then.
But I guess where is the demand coming from in the EU is this.
Something thats been kind of in the works for a long time in order to change. These regulations are they constrained in some ways food security wise or.
Reevaluating.
How they're regulating other aspect similar food system and this is being pulled along with it.
Thanks, Peter let me take that.
The overview and let you go to the specifics with the customers. So I think it would be helpful for them to understand the actual customers, we havent canola and how broad our demands from the customers and canola and the fact that we can out of these studies in the U K, but the biggest shock we have UK has been under a three year process to try to change their laws in the gene editing that doesn't include.
Trans genes gets treated as conventional breeding and there's really big consensus across Europe there.
The productivity in Europe is so gone down not having any gmos at all and so they need this law and we weathered it just safety study. They basically said our technology was safe and they drew it but that was surprised us was.
This was probably three months before we said that in our press release three months before we thought it would happen and then in the press release, they talked about taking it to parliament in February with June So we're pretty excited.
There is really not just forward progression, but theyre trying to speed up the process to get it behind us.
But Peter you might go.
It's really quite an encouraging moment for all of us.
In the U K you Havent passed us. So we do feel so do you see U K is a big deal because it allows us to start the progression of these products that are grown in Europe, Peter you want to add to the customers.
Yeah exactly right I think above your question around this is really on point because.
It's clear.
Clear that the EU.
Uh huh.
He is trying to accelerate this regulatory.
Which is which is not the normal.
State of affairs, and so a number of our customers are based in Europe and are very excited.
The opportunity to bring traits to market now this is the whole of Europe as 100 million acre market just hasn't had a lot of innovation in the last 30 years.
No to the point about improving sustainable agriculture climate resilience and food security they are big drivers for regulatory or these title wins.
For to bring improved products onto the marketplace has really seen by our customers as a huge step.
Fact is we are.
So many of our customers genetics and the trials in the U K.
Over the winter into the spring of 2024 that is a first for canola.
Winter Oilseed rape.
And it's exciting to see that because I think that.
Alignment.
Globally, you mentioned, Canada and your question is.
Is seeing a lot of progress on the regulatory front for harmonizing with the regulatory agencies are on.
No in Europe cycles of new genomic techniques, but essentially products from gene edited.
Technology.
Specifically ones like <unk>, where we have a non transgenic process and a non transgenic product.
Are they are harmonizing around the world and that really opens up global market for someone like save us.
That's really helpful.
Yeah, Yeah go ahead.
That's under contract already.
And the neat thing is to think about this 100 million acres has never had a wheat trade ever.
And we have three now so there's a big opportunity for us I'm sorry.
Many of the instructions.
No that's great additional color and to be clear. This also would cover imports into the EU.
That's correct.
These laws are once you do that it means when we develop a trade it it'll be accretive like conventional breeding coming into Europe for people, who aren't familiar with it Europe treats GMO products almost like drug. So it takes three to five years to get approval to suddenly everything we develop will have clear export approval and then I think that is.
It's going to be a big moment for the industry, but it will be a big moment for soybean.
To be able to introduce.
Got it.
Yeah understood.
This is could be huge.
Yeah.
Maybe just.
Looking at where there is GM.
Technology.
Existing in germplasm is there.
Interest, yes, simply just because of the speed at which you can introduce a trade.
And at a lower cost, where you will potentially be stack on <unk>.
These G M seeds.
As a significant part of what Youre doing overtime.
It totally is but pods chat or they don't have that trade and that's that's not one that's all about speed the fact that matters.
Our team had actually developed a real trades. So the first part is there is actually real trades and then the speed thing is is the fact that that.
Literally if you send us your germplasm and canola and other Peter and Greg I figured out to take a single cell from that germ plasm edit it and grow it.
Youre germ plasm, an 18 to 24 months, we can have our trait in your puzzle.
Do field trials.
And that's why that doesn't really.
It seems like that's an important distinction right because.
People might be tempted to think this is purely.
Gene edited.
Seeds, but the market is much bigger right because we're talking about pretty much all seeds, where your technology has relevance.
Yeah, that's something that in.
Yes, Bobby.
I think you hit on a really important point.
Okay.
Okay.
He is.
The recognition is that.
There was limitations to GMO major limitations on much you could do it.
In my mind, its like Windows 95, it's very old technology.
Bringing protein. It is it is just bringing forward trials that are really valuable in the market. So.
Theres markets, where we can exit that there's where there's been a complete barrier to getting gmos in way. The way you are free and clear with gene editing and then theres going to be other market small global market perhaps.
And North and South America, the way it will be adding traits to.
Genetics that already have trades and so that's.
The expansion opportunity is huge.
<unk> is the gene editing can address.
Slide 13 year like white mold disease resistance.
All of the technologies could not in the past.
Not only does it open up global markets it opens up opportunities in trade.
Able to be done using other technologies.
Well thank you both.
Somebody else ask a question here.
They're totally about his first four or five in a row.
Well thank you.
All good.
But Peter all of these breaking you can you tell me about India, India is such a big marketplace for both soybean and and and.
Yes.
Yeah I think.
India is really 100 million acres of rice.
And.
It's a very fragmented market, but it is it is has a huge appetite for trade and you know just recently.
Yeah, but released.
They are targeting 20% of that market, so 20 million acres around which is what they call direct seeded market in India. That's just an example of where you can.
Attrite like herbicide tolerance is something you really need to be able to do direct seeded Ross.
The appetite not only for opening up the market to better genetics, but also genetics. We've tried so India is a classic example of an emerging market in.
In agriculture that will take on traits in rice as well.
Canola, its a little bit different in India than.
Different genetics than that and what's in North America, but it is a very close relative.
Thanks Peter.
I apologize.
And our next question is from the line of Laurence Alexander with Jefferies. Please go ahead.
Hi, Good evening this is Kevin Estok on for Laurence.
Just one question to meet me I'd just to what extent has the volatility yes.
What extent has the volatility in the AG market.
I guess distracted customers from research partnerships or change your timetable and our milestones for next year.
I was going to live in a I'll leave it to Peter on the volatility of the markets. The good news is that we're really focused on.
Traits that are already developed and were trying to sell to so we're not trying to focus on new research agreements as much we want to see where we can develop but we have got out there.
We haven't seen decreased by more increase because people see we actually have.
Actual trade so they could buy Peter you on it.
No I think the volatility is there for sure I think.
We were trying to play our role is in the seed industry for increasing promise productivity.
And so you know the.
The appetite for outright because is increasing we see demand.
From a customers' additions.
Additional genetics that they would like to have traits in.
So that they can deliver.
Better profit Saddam is by increasing their productivity so the volatility actually in my mind.
It accelerates the demand and requirements for.
Technologies like Steve this is delivering to the customers.
Got it okay. Thank you very much.
It is a distinction between strict yield stuff and specific.
Trade stuff right specific.
Specific productivity aspects of trade.
Which has been interesting I think but thanks so much.
No problem.
<unk>.
Yeah.
And Mr. <unk> there are no further questions at this time I will now turn the call back to you for closing remarks.
Thanks, David and thank the questions I think that our goal in these calls now is to help you understand the progression, we have actual trades and and and and because of that every quarter. Like this was the field study quarters every quarter there'll be aspects to be able to attract how well we are towards our goal of having it stays in that field.
Being accessed by farmers and so I think that the things, we've really talked about our <unk>.
One.
Besides our mapping our progression the two big things everybody is going to see is can we do soybean and they can get it off because that's just a big value moment for us and to Europe seems to be accelerating and so as quick as we can get Europe behind us suddenly we'd become a real three crop fives trade business model and we've become truly global.
We're really excited by it.
And.
The most important part of it is just sort of understanding our progression. Following though you guys have any more questions. Please call. It's a really exciting moment for us for us to build the trucks, Peter you want to add anything or that's it.
I think thats a good summation right.
It's definitely an even playing some quite well.
Where we are.
Cool Thanks, guys. Thanks, Tim I think we're done.
<unk>.
That does conclude your conference call for today, we thank you for your participation and ask that you. Please disconnect your lines.
[music].
Okay.
Okay.
[music].